News

29

Jan, 2021

Farewell to a great man

 

Penta joins our colleagues across the world in mourning the passing of our friend and research collaborator, Professor James Hakim, who died on 26 January 2021 from COVID-19 complications. He will be greatly missed by all those who had the privilege of knowing him. Professor Hakim was a prominent figure and pathfinder in the field of TB, HIV/AIDS and clinical research in Africa and his passing comes at a time where the importance of bringing HIV to the forefront has never been more significant for the world’s ability to achieve [...]
READ MORE

26

Jan, 2021

Prof. Timo Vesikari talks to us about COVID-19 vaccines and children

Tags: , ,

In December 2020 Penta held its annual Scientific Meeting. Despite the unusual get together due to COVID-19, we shared great science together. Among the experts invited was Timo Vesikari, a vaccine specialist who provided an insightful overview of the current scenario around COVID-19 vaccine development. He agreed to an interview with us and shed some light on our understanding of COVID-19 vaccines and how they impact children. Read the interview here

READ MORE
Antimicrobial Resistance

21

Jan, 2021

Speeding up the development and approvals of new antibiotics for children

Tags:

In these difficult times, it is important to remain focused on improving outcomes for children with serious multidrug-resistant infections globally. Antimicrobial Resistance (AMR) represents a substantial threat to the Sustainable Development Goals (SDGs), with a large impact on the health of children worldwide. However, there is quieter limelight on the growing threat of AMR to child health. Carlo Giaquinto, Emmanuel Roilides,  Irja Lutsar, and Mike Sharland – members of Penta ID Network, along with other international researchers have published an article to highlight this issue and call for clear steps […]

READ MORE

21

Jan, 2021

EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir

Tags: , ,

On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part, on data from our ODYSSEY trial, which we are conducting in close collaboration with the MRC CTU at the University College London. The EMA also authorised updating dosing recommendations for dolutegravir film-coated tablets (10mg, 25mg and 50mg) for children six years and older and weighing at least 14kg, bringing these in line with the World Health Organization weight bands. […]

READ MORE

17

Dec, 2020

First patient enrolled in PediCAP trial

Tags: , ,

We are proud to announce that on the 7th of December 2020, the PediCAP team at Makerere University at the China-Uganda Friendship Hospital Naguru (Kampala, Uganda) recruited the very first participant into the PediCAP clinical trial. Though the study experienced a delayed start due to the COVID-19 pandemic, the drive and commitment of the Ugandan team ensured all ethical and regulatory approvals were acquired by June 2020, and that the trial drugs and other necessities were available in October and November 2020. The site officially launched on the 4th of […]

READ MORE

10

Dec, 2020

Cascade of care in children and adolescents with HIV in the Russian Federation

Tags: , ,

The Cascade of Care, more commonly known as the HIV care continuum, is a calculation of how many people in a specific population diagnosed with HIV are initially linked to care, retained in care and have achieved viral suppression. It is an important tool in measuring success in controlling the HIV infection, identifying gaps in national HIV/AIDS strategies and set directions to improve care. On behalf of EPIICC and REACH researchers, Anna Turkova presented on the Cascade of Care of HIV positive children and adolescents in three Russian centres at […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities